3.72
Indaptus Therapeutics Inc Borsa (INDP) Ultime notizie
INDP Q4 2025 Earnings: EPS Misses Estimates Amid Continued R&D InvestmentNet Income Trends - newsline.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
INDP Q4 2025 Earnings: EPS Misses Estimates, Stock Tumbles 42.62%Quarterly Earnings Report - newsline.com
Indaptus Therapeutics (INDP) Plunges 42% as Selling Pressure IntensifiesUp Down Volume - newsline.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Indaptus Therapeutics, Inc. Files Form 8-K Announcing CEO Change – Junyi Dai Appointed CEO - Minichart
Indaptus Therapeutics Announces Recent Board and Leadership Changes - TipRanks
Indaptus Therapeutics directors David E. Lazar and Avraham Ben-Tzvi resign; Walt A. Linscott steps down as COO - TradingView
Leadership shifts at Indaptus Therapeutics (NASDAQ: INDP) as directors and COO exit - Stock Titan
Indaptus Therapeutics (INDP) Jumps 53.8% Amid Heavy Volume as Investors Focus on Financing/strategic-option Uncertainty - Moomoo
Indaptus Therapeutics (INDP) jumps 53.8% amid heavy volume as investors focus on financing/strategic-option uncertainty - Quiver Quantitative
INDP Q4 2025 Earnings: EPS Misses Estimates Amid No Revenue; Stock Surges Over 114%Revenue Beat Analysis - newsline.com
INDP - Finviz
INDP Q4 2025 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Focuses on Pipeline MilestonesMargin Expansion Trends - newsline.com
Indaptus Therapeutics Drops on Cash Runway Worries - Bez Kabli
Indaptus Therapeutics Inc. (INDP) Plunges 9.8% as Shares Approach Key Support ZoneGap Down Bounce Plays - Newser
INDP Q4 2025 Earnings: EPS Misses Estimates as Pre-Clinical Costs Continue, Stock Declines 9%Revenue Growth Outlook - newsline.com
Indaptus Therapeutics Q4 2025 Earnings: EPS Misses Estimates on Minimal Revenue, Stock SurgesFree Cash Flow Trends - The Legal Advocate
Indaptus Therapeutics Inc. (INDP) Q4 2025 Earnings: Deeper Loss, Yet Shares Surge on Pipeline ProgressRevenue Warning Signal - Newser
Indaptus Therapeutics (INDP) Surges 15%: Biotech Stock Breaks Above Key ResistanceMarket Hype Signals - Newser
Earnings Scheduled For May 15, 2026 - Sahm
Indaptus Therapeutics, Inc. Reports Substantial Doubt About Going Concern and Highlights Key Risks in Q1 2026 10-Q Filing - Minichart
Indaptus Therapeutics Reports Q1 2026 Financial Results, Management Changes, and Strategic Review Amid Cash Constraints - Minichart
Indaptus Therapeutics reassesses decoy platform as cash dwindles - grafa.com
Indaptus Therapeutics Q1 Financial Analysis - Intellectia AI
Indaptus Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Indaptus Therapeutics (NASDAQ: INDP) cuts R&D, warns on cash runway - Stock Titan
Cash drops at Indaptus (Nasdaq: INDP) as Q1 2026 loss narrows - Stock Titan
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics Q1 net loss narrows as expenses fall - TradingView
Press Release: Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
INDP Should I Buy - Intellectia AI
TradingKey - TradingKey
INDP | Indaptus Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Indaptus Therapeutics Company Profile & Introduction - Moomoo
INDP Q1'26 Earnings: EPS estimate is (1.87) USD - TradingView
Large holders in Indaptus (INDP) revise stakes and end group status - Stock Titan
Indaptus Therapeutics (INDP) Stock: Is It a Good Entry Point | Indaptus Therapeutics misses EPS views, no revenue - newser.com
Is It a Good Entry Point | Indaptus Therapeutics misses EPS views, no revenueVerified Stock Signals - Newser
Indaptus Therapeutics Appoints Tim Ruan and Johnny Fox Arrowsmith as Independent Directors; Amendment Reflects Legal Name Change - Minichart
Indaptus Therapeutics (INDP) refreshes board with two independents as one resigns - Stock Titan
Indaptus Therapeutics (INDP) reshapes board with two new independents and one exit - Stock Titan
Indaptus Therapeutics Adds Independent Directors Amid Board Refresh - TipRanks
Indaptus Therapeutics appoints two new independent directors and announces board changes By Investing.com - Investing.com South Africa
Indaptus Therapeutics appoints two new independent directors and announces board changes - Investing.com
Indaptus Therapeutics names Tim Ruan and Yi Zhang as independent directors; Matthew McMurdo resigns - TradingView
Indaptus (INDP) director Lu Qinglai submits initial Form 3 ownership - Stock Titan
Is Indaptus Therapeutics (INDP) stock trading at a premium valuation (Momentum Building) 2026-04-20 - newsline.com
Indaptus Therapeutics (INDP) Stock: Why Automation Investment (Soars) 2026-04-18Trend Analysis - Xã Châu Thành
Sino Lion Ventures Ltd Net Worth (2026) - GuruFocus
Junyi Dai Net Worth (2026) - GuruFocus
Yun Yao Net Worth (2026) - GuruFocus
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):